Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 14Leukemia, Myeloid, Acute 7Neoplasms 3Neoplasm Metastasis 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neuroblastoma 2Liver Neoplasms 2Hepatoblastoma 2Fibrolamellar hepatocellular carcinoma 2Tongue Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Sarcoma, Myeloid 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors 1Melanoma 1Gastrointestinal Stromal Tumors 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

trametinib 1spartalizumab 1pembrolizumab 1lenvatinib 1gallium Ga 68 dotatate 1dabrafenib 1Sorafenib 1Sodium Iodide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, Hurthle cell × Sorafenib × 1 year × Clear all
NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
35 enrolled 14 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡